A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Finding Study of ORG 2766 in the Prevention or Delay of Cisplatin-Induced Neuropathies in Women with Ovarian Cancer
Open Access
- 30 November 1997
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 67 (2) , 172-177
- https://doi.org/10.1006/gyno.1997.4832
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Prevention of Cisplatin Neurotoxicity with an ACTH(4–9) Analogue in Patients with Ovarian CancerNew England Journal of Medicine, 1990
- Vibration perception and thermoperception as quantitative measurements in the monitoring of cisplatin induced neurotoxicityJournal of the Neurological Sciences, 1989
- Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721Cancer, 1988
- A Rationale for the Use of Melanocortins in Neural InjuryPublished by Springer Nature ,1988
- Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studiesCancer, 1984
- RANDOMISED TRIAL COMPARING TWO COMBINATION CHEMOTHERAPY REGIMENS (HEXA-CAF VS CHAP-5) IN ADVANCED OVARIAN CARCINOMAThe Lancet, 1984
- Evidence that the neurotrophic actions of α-MSH may derive from its ability to mimick the actions of a peptide formed in degenerating nerve stumpsJournal of the Neurological Sciences, 1984
- Neurotrophic factors and regeneration in the peripheral nervous systemPsychoneuroendocrinology, 1984
- Neuropeptides derived from pro-opiocortin: behavioral, physiological, and neurochemical effects.Physiological Reviews, 1982
- Peripheral neuropathy and ophthalmologic toxicity after treatment with cis-dichlorodiaminoplatinum IIZeitschrift für Krebsforschung und Klinische Onkologie, 1980